Vernakalant Hydrochloride for Rapid Conversion of Atrial Fibrillation - Atrial Arrhythmia Conversion Trial


Currently, ibutilide is the only agent that is Food and Drug Administration approved for acute conversion of atrial fibrillation (AF). Other agents that are frequently used, such as amiodarone, are associated with modest efficacy and frequent side effects. Vernakalant hydrochloride is a newer agent, which showed promising results in a placebo-controlled phase II trial. The goal of this trial was to study the safety and efficacy of vernakalant in acute conversion of AF.